-PDS-0330 is characterized by favorable pharmacodynamics and pharmacokinetics in vitro and in vivo-PDS-0330 has higher affinity and specificity binding to claudin-1 compared to other claudins-Reduction in anoikis and therapy resistance of cancer cells-Inhibition of tumor growth in vivo with no major cytotoxicity -Synergistic effect with 5-FU in vivo-Reduction of claudin-1-dependent CRC chemoresistance. This evidence concerns the gene CLDN1 and neoplasm.